A novel VTA for vascularised solid tumours. Phase II trials as single agent ongoing in colorectal and liver cancer, and in mesothelioma. Phase II trials in combination ongoing with Xelox in colorectal cancer, with doxorubicin in small-cell lung and ovarian cancer, and with platinum-based regimens in non-small-cell lung cancer
Cell therapy enabling safe haploidentical haematopoietic stem cell transplantation (HSCT) for the treatment of haematological malignancies. Phase III in high-risk acute leukaemia started in Italy
Cancer therapeutic vaccine for solid tumours, designed to use the patient's own T cells as tumour antigen carriers. Phase I/II trial ongoing in advanced/metastatic melanoma.
 




Feb 2, 2008
MolMed appointed Dr. Cynthia Giuliani as Director of Human Resources


Jan 22, 2008
MolMed gets approval to start Phase III of TK in high risk acute leukaemia


Dec 3, 2007
MolMed appointed Dr. Daniele Pieraccioli as Director of Intellectual Property


Oct 30, 2007
MolMed sponsor of ESGCT Young Investigator Award in memory of Salvatore Toma


more news